The combined company will focus on developing treatments for hepatitis B virus, a major global health problem, while also pursuing Tekmira’s other product candidates. The transaction brings together the companies’ broad expertise in antiviral drug development. A multi-office Dorsey team served as U.S. legal advisor to Tekmira in this transaction.